Vor Biopharma (NASDAQ:VOR) Stock Jumps 7.2% Following Analyst Upgrade

Vor Biopharma Inc. (NASDAQ:VOR)’s share price rose 7.2% on Thursday after Citigroup upgraded the stock to a strong-buy rating. The stock traded as high as $20.02 and last traded at $20.0950. Approximately 122,578 shares were traded during trading, a decline of 88% from the average daily volume of 1,057,865 shares. The stock had previously closed at $18.75.

VOR has been the topic of several other reports. Wedbush upped their price target on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, August 12th. Wall Street Zen upgraded Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings raised Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 14th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Hedge Funds Weigh In On Vor Biopharma

Several large investors have recently made changes to their positions in the company. Braidwell LP boosted its holdings in Vor Biopharma by 22.8% during the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock worth $10,551,000 after buying an additional 106,330 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Vor Biopharma during the first quarter valued at $2,298,000. Bank of America Corp DE grew its position in Vor Biopharma by 28,408.1% during the first quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock valued at $2,014,000 after buying an additional 112,496 shares during the period. Bank of New York Mellon Corp acquired a new stake in Vor Biopharma during the second quarter valued at $1,799,000. Finally, Simplify Asset Management Inc. acquired a new stake in Vor Biopharma during the first quarter valued at $955,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Price Performance

The business’s fifty day simple moving average is $21.57 and its two-hundred day simple moving average is $18.37.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). As a group, equities research analysts expect that Vor Biopharma Inc. will post -2.56 EPS for the current fiscal year.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company’s approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor’s technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets.